Amarin

Would Pfizer Shareholders Win With an Acquisition of Amarin?
Would Pfizer Shareholders Win With an Acquisition of Amarin?
Motley Fool
Pfizer
Amarin
M&A
Flag link:
Pick your post-JPM buzz: Pfizer eyes Amarin, Biogen shops anyone with 'multiple' phase 3 drugs
Pick your post-JPM buzz: Pfizer eyes Amarin, Biogen shops anyone with 'multiple' phase 3 drugs
Fierce Pharma
JPMHC 2019
M&A
Pfizer
Biogen
Amarin
Flag link:
The winners and losers from JPM 2019
The winners and losers from JPM 2019
Biopharma Dive
JPMHC 2019
Loxo Oncology
SAGE Therapeutics
Amarin
FDA
M&A
Flag link:
JP Morgan Healthcare Conference Update: Sage, Mersana, Shutdown Woes and Babies
JP Morgan Healthcare Conference Update: Sage, Mersana, Shutdown Woes and Babies
BioSpace
JPMHC 2019
SAGE Therapeutics
SAGE-217
Mersana
Novavax
Denali Therapeutics
AstraZeneca
Amarin
FDA
government shutdown
Flag link:
Pharma's 2019 Prognosis Hinges on These Key Themes
Pharma's 2019 Prognosis Hinges on These Key Themes
Bloomberg
drug pricing
Amarin
Vascepa
IPOs
cancer
Flag link:
The Most Promising Biotech Names Heading Into 2019
The Most Promising Biotech Names Heading Into 2019
Investopedia
biotech
AbbVie
Novavax
Amarin
TG Therapeutics
Flag link:
2 Biotech Stocks Poised for Big Gains in 2019
2 Biotech Stocks Poised for Big Gains in 2019
Motley Fool
Amarin
Vascepa
Novavax
ResVax
Flag link:
Amarin raises $200M ahead of Vascepa push
Amarin raises $200M ahead of Vascepa push
BioCentury
Amarin
Vascepa
Flag link:
Amarin's Vascepa trial stirs data debate as stock drops 10%
Amarin's Vascepa trial stirs data debate as stock drops 10%
Biopharma Dive
Amarin
Vascepa
Flag link:
Amarin's Fish-Oil-Derived Drug Shows Great Promise — With Big Caveats
Amarin's Fish-Oil-Derived Drug Shows Great Promise — With Big Caveats
Forbes
Amarin
Vascepa
Flag link:
Why Amarin Stock Jumped 28% in October -- and Why a Bigger Move Could Come Soon
Why Amarin Stock Jumped 28% in October -- and Why a Bigger Move Could Come Soon
Motley Fool
Amarin
Vascepa
Flag link:
Experts question Amarin's early touting of Vescepa data ahead of detailed results
Experts question Amarin's early touting of Vescepa data ahead of detailed results
Endpoints
Amarin
Vascepa
heart disease
Flag link:
[video+transcript] How Big Could Amarin's Vascepa Be?
[video+transcript] How Big Could Amarin's Vascepa Be?
Motley Fool
Vascepa
Amarin
Flag link:
3 Drugmakers Not Pleased With Amarin's Fish Oil Triumph
3 Drugmakers Not Pleased With Amarin's Fish Oil Triumph
Yahoo/Motley Fool
Amarin
Vascepa
Amgen
Sanofi
Regeneron
Flag link:
Amarin Soars as Fish Oil Pill Cuts Risk of Strokes in Long-Awaited Study
Amarin Soars as Fish Oil Pill Cuts Risk of Strokes in Long-Awaited Study
Xconomy
Amarin
fish oil
strokes
Vascepa
Flag link:
Why Amarin Corporation Skyrocketed 23.9% in August
Why Amarin Corporation Skyrocketed 23.9% in August
Motley Fool
Amarin
Vascepa
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings
Yahoo/Benzinga
Adamis
GSK
Sangamo BioSciences
Roche
Bluebird Bio
ProQR Therapeutics
Geron
Amarin
Palatin
EyeGate
Galactin
Omeros
Atossa Genetics
Flag link:
Amarin Corporation, CRISPR Therapeutics, and Geron Corporation could all see big gains next week
Amarin Corporation, CRISPR Therapeutics, and Geron Corporation could all see big gains next week
Motley Fool
Amarin
CRISPR Therapeutics
Geron
Vascepa
Vertex Pharmaceuticals
CTX001
JNJ
imetelstat
Flag link:
Analysts: Amarin poised for huge gains if Vascepa trial comes back positive
Analysts: Amarin poised for huge gains if Vascepa trial comes back positive
Medical Marketing and Media
Amarin
Vascepa
Flag link:
Amarin's Vascepa goes on TV to lay groundwork for impending CV outcomes data
Amarin's Vascepa goes on TV to lay groundwork for impending CV outcomes data
Fierce Pharma
Amarin
Vascepa
physicians
television ads
Flag link:

Pages